Psychiatry
Anxiety Disorder
33
Pipeline Programs↗
2
Active Trials↗
18
Companies Involved↗
Anxiety Disorder is a moderately active landscape with 33 programs across 18 companies. The most active players are Pfizer, Johnson & Johnson, Merck & Co.. 18 therapies are approved with 6 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 36
Analysis
Trial Status
31
clinical trials
Completed18 · 58%
Unknown status7 · 23%
Withdrawn2 · 6%
Suspended1 · 3%
Recruiting1 · 3%
Terminated1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
31 trials
Fluoxetine vs CBT in Childhood Anxiety Disorders
Active, not recruiting·—·Phase 3·NCT04760275·316 enrolled
Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity
Completed·CCentre for Anxiety, Attention Deficit and Trauma, Ontario, Canada·Phase 4·NCT01863459·42 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)